News

A new study led by Dr. Zhi-tao Ying from Peking University Cancer Hospital has demonstrated the safety and efficacy of IM19 CAR-T cell therapy in treating relapsed and refractory B-cell hematologic malignancies. Published in the Chinese Journal of New Drugs, the study reports that 11 out of 12 patients achieved complete remission with no severe adverse effects, showcasing the potential of IM19 as a promising treatment option for patients with limited alternatives.

Over the past five decades, research on Natural Killer (NK) cells has revolutionized our understanding of innate immunity, offering promising new avenues for cancer and viral therapies.

The 2024 Annual Training for Clinical Blood Management and Transfusion Technology in Sanhe City was successfully held at Yanda Ludaopei Hospital. This event aims to enhance clinical blood management and transfusion safety through comprehensive training sessions attended by over 100 healthcare professionals from various medical institutions.

A pioneering study at Erlangen University Hospital successfully treated a 16-year-old girl with severe systemic lupus erythematosus (SLE) using CAR-T cell therapy. This marks the first use of this treatment for pediatric lupus, offering new hope for children with autoimmune diseases.

A recent study in Nature Communications reveals key insights into the intrinsic signaling pathways that modulate the effectiveness of targeted protein degradation using PROTACs. This discovery could pave the way for more effective treatments for cancer and other diseases.

Ensuring a safe and comfortable treatment experience for leukemia patients involves meticulous daily care, including environmental sanitation, personal hygiene, nutrition, and appropriate exercise. This guide provides essential tips for effective daily care to support recovery.

A recent study highlights the efficacy and safety of NS7CAR-T cell therapy in treating relapsed or refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and T-cell lymphoblastic lymphoma (R/R T-LBL). This therapy offers new hope for patients with these aggressive forms of cancer.

A recent study highlights the promising results of CD7-targeted chimeric antigen receptor (CAR) T cell therapy in treating patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

The 66th Annual Meeting of the American Society of Hematology (ASH) will be held from December 7-10, 2024, at the San Diego Convention Center, showcasing groundbreaking research and advancements in hematology.

The 12th Annual Lu Daopei Hematology Forum is set to take place on August 23-24, 2024, at the Beijing International Convention Center. Join us for insightful discussions and the latest advancements in hematology.

Despite the ongoing challenges in industrialization and commercialization, CAR-T therapy's limitations are being addressed by a promising new approach: Tumor-Infiltrating Lymphocyte (TIL) therapy. This breakthrough heralds a new era in the fight against solid tumors.

A revolutionary treatment for cancers may also be able to treat and reset the immune system to provide long-term remission or possibly even cure certain autoimmune diseases.